$1.60
0.93%
Nasdaq, Oct 21, 04:00 pm EDT. Closed.
ISIN
US03835L1089
Symbol
APVO

Aptevo Therapeutics Inc Stock price

$1.60
-0.21 11.60% 1M
-3.50 68.63% 6M
-7.83 83.03% YTD
-26.66 94.34% 1Y
-192,232.64 100.00% 3Y
-8,785,337.60 100.00% 5Y
-18,789,723.20 100.00% 10Y
-65,640,958.40 100.00% 20Y
Nasdaq, Closing price Wed, Oct 21 2026
-0.02 0.93%
ISIN
US03835L1089
Symbol
APVO
Industry

Is Aptevo Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,102 stocks worldwide.

Key metrics

Basic
Market capitalization
$2.9m
Enterprise Value
$-6.9m
Net debt
positive
Cash
$9.8m
Shares outstanding
1.4m
Valuation
P/E
negative
P/S | estimate
- | -
EV/Sales | estimate
- | -
EV/FCF | ex SBC
0.3 | 0.3
P/B
0.5
Financial Health
Equity Ratio
63.9%
Return on Equity
-
ROCE
-288.2%
ROIC
-
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$190.0k | -
SBC as % of FCF
-
SBC Growth 1Y
111.1%
Share Count Growth 1Y
688.9%
Shareholder Yield
-688.9%
Financials
Revenue | estimate
$0.0 | $0.0
EBITDA
$-26.7m
EBIT
$-26.9m
Net Income
$-28.1m
Free Cash Flow | ex SBC
$-25.3m | $-25.5m
Growth
Revenue | estimate
- | -
EBITDA
-11.0%
EBIT
-10.6%
Net Income
-16.9%
Free Cash Flow
-3.6%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow | ex SBC
- | -
More
EPS
$-23.5
FCF per Share
$-17.8
Short interest
7.7%
Employees
33
Rev per Employee
-

Aptevo Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Aptevo Therapeutics Inc forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Aptevo Therapeutics Inc forecast:

Buy
86%
Hold
14%

Aptevo Therapeutics Inc Events

Upcoming Event
NOV
4
Q3 2026 Earnings Call
in 14 days
View Past Earnings Reaction

Financial data from Aptevo Therapeutics Inc

Jun '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 12 12
13% 13%
-
- Research and Development Expense 15 15
9% 9%
-
-27 -27
11% 11%
-
- Depreciation and Amortization 0.20 0.20
23% 23%
-
EBIT (Operating Income) EBIT -27 -27
11% 11%
-
Net Profit -28 -28
17% 17%
-

In millions USD.

Don't miss a Thing! We will send you all news about Aptevo Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aptevo Therapeutics Inc Stock News

Neutral
Accesswire
●
7 days ago
Next generation multispecific technology designed to coordinate innate and adaptive immune activity within the tumor microenvironment SEATTLE, WA / ACCESS Newswire / October 14, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel bispecific and multispecific immunotherapies for the treatment of cancer, today announced that the Compan...
Neutral
Accesswire
●
27 days ago
Company Making Critical Progress in Scalable Manufacturing and Preparing the Lead Trispecific Candidate for Future Human Testing Trispecifics Combine Three Complementary Cancer-Fighting Functions in One Molecule, Enabling a Coordinated Approach to Recognizing Cancer, Activating Immune Cells and Addressing Tumor Defenses SEATTLE, WA / ACCESS Newswire / September 24, 2026 / Aptevo Therapeutics In...
Neutral
Accesswire
●
about 2 months ago
Remission results nearly double published ven/aza outcomes in patients with historically limited treatment success SEATTLE, WA / ACCESS Newswire / September 3, 2026 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, today announced a 93% clinical benefit rate with its mipletamig triplet in evaluable front...
More Aptevo Therapeutics Inc News

Company Profile

Aptevo Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics to improve patients lives. Its pipeline includes APVO210, APVO436, ROR1 Candidate, and ALG.APV-527. The company was founded on February 22, 2016 and is headquartered in Seattle, WA.

Head office United States
CEO Mr. White
Employees 33
Founded 2016
Website aptevotherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today